So far, the European LeukemiaNet and the National Comprehensive Cancer Network (NCCN) have presented international guidelines on CML molecular approaches, especially those related to BCR::ABL1 expression. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.